Update (June 17, 2026): Bedinvetmab Plus Physiotherapy Outperforms Bedinvetmab Alone on Pain Threshold in Dogs With Hip OA

TL;DR

A 2026 randomised comparative effectiveness trial found that combining bedinvetmab with photobiomodulation and pulsed electromagnetic field therapy (physiotherapy) provided superior pain threshold improvement from Day 30 onward compared with bedinvetmab alone in dogs with hip osteoarthritis.

What just dropped

• Cidral et al. 2026 (Vet Res Commun 50:198, March 2026; DOI 10.1007/s11259-026-11133-3; PMID 41824140; open access): prospective, randomised, comparative effectiveness trial; 30 dogs with hip osteoarthritis allocated to bedinvetmab + physiotherapy group (BPG) or bedinvetmab alone (BG).
• Physiotherapy (photobiomodulation and pulsed electromagnetic field therapy) was performed twice a week over 90 days in the BPG.
• Pain was assessed by algometry and owner-completed Canine Brief Pain Inventory (CBPI).
• Both groups showed significant clinical improvement from baseline (p<0.001) for Pain Severity Score and Pain Interference Score (CBPI).
• In algometry, the BPG showed a significant increase in pain threshold from Day 15 (D15) and was superior to BG from Day 30 (D30; p=0.027), with more pronounced differences at Days 60, 75, and 90 (p<0.001).

Context

This trial is notable because it tests bedinvetmab (Librela/Beransa), the anti-NGF monoclonal antibody, as a backbone onto which physiotherapy is added rather than as a monotherapy comparator. The study design allows both groups to benefit from bedinvetmab's mechanism and isolates the additive effect of physical rehabilitation.

The finding that algometric (objective) pain threshold diverged between groups from Day 30 -- with more pronounced differences at later time points -- suggests a time-dependent synergy rather than an immediate additive effect. Owner-reported CBPI outcomes improved in both groups without a reported between-group statistical comparison in the abstract. The trial is not powered to establish dose sparing or long-term outcomes beyond 90 days.

What this changes in bedinvetmab-librela-adverse-events-dogs (https://www.thevoyage.ai/forvets/knowledge/bedinvetmab-librela-adverse-events-dogs)

The Cidral 2026 trial does not affect the safety or adverse-event profile of bedinvetmab itself but adds context to its use within multimodal OA management. Objective pain threshold improvement is superior when bedinvetmab is combined with photobiomodulation and PEMF, reinforcing that anti-NGF antibody therapy is most effective in a multimodal rehabilitation framework. This is consistent with the direction of multimodal canine OA management guidelines.

References

1. Cidral LO, Serighelli-Junior G, de Souza SF, de Castro Vilani RGD. Bedinvetmab, alone or in combination with photobiomodulation and pulsed electromagnetic field therapy, on pain and quality of life in dogs with hip osteoarthritis. Vet Res Commun. 2026 Mar;50(3):198. DOI: 10.1007/s11259-026-11133-3 (https://doi.org/10.1007/s11259-026-11133-3)

Related reads

• Bedinvetmab (Librela) Adverse Events in Dogs: Neurological Safety Profile
• Grapiprant (Galliprant) for Canine Osteoarthritis Pain: EP4 Antagonism and Clinical Evidence
• Enflicoxib (Daxocox) for Canine Osteoarthritis: A Once-Weekly COX-2 Selective NSAID